Advertisement

Andrea Cercek, MD

Articles

Advice for Providers Treating Metastatic Colorectal Cancer

August 3rd 2022

Experts provide advice for providers treating patients with metastatic colorectal cancer and highlight exciting potential combination treatments on the horizon.

Novel Therapies in HER2-Amplified Metastatic Colorectal Cancer

August 3rd 2022

Dr Andrea Cercek reviews key clinical trials in HER2-amplified colorectal cancer treatment and considers how the approval of new therapies will impact the current treatment landscape.

Treatment Options after Disease Progression in Metastatic Colorectal Cancer

July 22nd 2022

Andrea Cercek, MD, explains the potential treatment options for metastatic colorectal cancer after disease progression.

Individualizing Therapy in HER2+ Metastatic Colorectal Cancer

July 22nd 2022

Dr Jaclyn Hechtman presents the profile of a patient with HER2+ metastatic colorectal cancer and has a conversation with Dr Andrea Cercek on how to personalize frontline therapy selection in each patient.

The Future of Molecular Testing in Colorectal Cancer

July 13th 2022

A look at how the molecular testing landscape in colorectal cancer is evolving.

Challenges and Barriers to Colorectal Cancer Molecular Testing

July 13th 2022

Drs Hechtman and Cercek discuss how practice setting affects molecular testing options and the barriers patients face in receiving testing.

Detecting HER2 Amplification in Colorectal Cancer

July 6th 2022

Experts describe which patients should be screened for HER2 amplification in colorectal cancer and how best to detect it.

Molecular Testing Options in Colorectal Cancer

July 6th 2022

A pathologist explains how she chooses between a variety of molecular testing technology options in colorectal cancer.

Overview of Molecular Testing in Colorectal Cancer

June 15th 2022

Jaclyn Hechtman, MD, provides an overview of the history of molecular testing in colorectal cancer and how testing has evolved.

Dr. Cercek on Targeted Strategies in BRAF-Mutant mCRC

February 21st 2020

Andrea Cercek, MD, discusses targeted strategies in BRAF-mutant metastatic colorectal cancer.

Dr. Cercek on the Impact of Tumor Sidedness on Frontline Treatment in mCRC

February 19th 2020

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the impact of tumor sidedness on frontline treatment decisions in metastatic colorectal cancer (mCRC).

Dr. Cercek on the Need for Treatment Options in KRAS-Mutated mCRC

February 11th 2020

Andrea Cercek, MD, discusses the need for treatment options in KRAS-mutated metastatic colorectal cancer (mCRC).

Dr. Cercek on the Importance of Molecular Testing in CRC

February 8th 2020

Andrea Cercek, MD, discusses the importance of molecular testing in colorectal cancer.

Dr. Cercek on Chemotherapy Resistance in dMMR Rectal Cancer

November 20th 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chemotherapy resistance in mismatch repair deficient rectal cancer.

Dr. Cercek on Induction Chemotherapy in Mismatch Repair Deficient Rectal Cancer

October 29th 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses induction chemotherapy in patients with mismatch repair deficient rectal cancer.

Advertisement
Advertisement